Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Gilead will construct three new facilities in the U.S., while upgrading three others. The company claims the investment will ...

The independent experts will meet on May 22 to discuss updates to the COVID-19 vaccine for the upcoming season.

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision to declare the end of the shortage of Novo Nordisk’s semaglutide, Judge ...

In this episode of Denatured BioSpace's head of insights Lori Ellis discusses the public health consequences of vaccine ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

The Massachusetts biotech will focus its efforts and resources into cemsidomide, an oral drug candidate being trialed for ...

M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing ...

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

MassBio’s new report outlines several concerns, including NIH cuts undermining the research engine, FDA reductions delaying ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...